Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Longduoduo Company Limited (LDDD)
Hohhot, CN
Longduoduo Company Limited, along with its associated entities, operates within the People's Republic of China, focusing on providing proactive health management and preventative medical services. The company's comprehensive suite of offerings includes health screenings, diverse treatment options, and specialized healthcare products, all aimed at reducing the likelihood of severe conditions such as myocardial infarction (heart attacks), cerebral infarction (strokes), hemiplegia (paralysis), and other cardiovascular and cerebrovascular diseases. These services are delivered through an extensive network of external collaborators, including independent healthcare providers, product vendors, and sales representatives. Additionally, Longduoduo features a range of advanced therapeutic interventions. These encompass meridian-regulating and consciousness-restoring techniques, a double blood purification process, immunological ozonated autohemotherapy, platelet-rich plasma therapy, relaxation techniques, vegetative nerve regulation, and microwave therapy. Established in 2020, the firm's primary operational base is located in Hohhot, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -14.04% | -14.04% | -89.78% | -99.18% | -94.90% | -94.90% | -94.90% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%-42.3% Q1'26: -75.9% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-63.6% Q1'26: -52.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+0.3% Q1'26: -177.5% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+13.0% ★ Q1'26: -105.4% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%— Q1'26: +216.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.03× ★ Q1'26: -0.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zhang Liang | 15.39M | 51.30% | 15.39M | — | 15.39M | 10.00 | IN | People’s Republic of China | 2023-12-12 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-25 | Ma Jiayang | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-27 | Zhang Liang | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 15,392,015 | — | ↗ |
| 2023-11-27 | Xu Huibo | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-27 | Wu Binbin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-27 | Shan Bo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-27 | Liping Kang | Officer | — | D | Common Stock | 0 | 0.00 | — | 5,000 | — | ↗ |
| 2023-11-27 | Li Zhijie | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-27 | Hongxiao Zhou | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Huibo Xu | President & Chairman | 36.0K | male |
| Hongxiao Zhou | Chief Executive Officer, Secretary & Director | 22.2K | female |
| Liping Kang | Chief Financial Officer | 21.9K | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LDDD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
